Clinical trials: Plasmodium Falciparum Infection
Falciparum Malaria
Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania
This is a phase Ib double-blind randomized placebo controlled age-deescalating trial to assess sagety and immunogenicity of two virosome formulated anti-malaria vaccine components (PEV 301 and PEV 302) administered in combination…
- Trial name
- PMAL03 (NCT00513669)
- Testing
- PEV 301& 302 in virosomes, Inflexal V (active comparator)
- Where
- Tanzania
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Malaria
Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children
This study is a single site, randomized, double-blind, placebo-controlled trial. The trial will assess the safety, tolerability, immunogenicity and vaccine efficacy (VE) of PfSPZ Vaccine in Gabonese children that are naturally…
- Trial name
- NCT03521973
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Gabon
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria,Falciparum, Feasibility
Malaria Vaccine Pilot Evaluation
The RTS,S/AS01 malaria vaccine is being introduced sub-nationally in phased pilot introductions through the EPI programmes in Malawi Ghana and Kenya.
- Conditions
- Malaria,Falciparum, Feasibility, Safety, Mortality
- Trial name
- MVPE (NCT03806465)
- Testing
- Feasibility survey, Sentinel hospital surveillance, Community mortality surveillance
- Where
- 3 sites in Ghana, Kenya and 1 more
- Volunteers
- 30,124 people, healthy volunteers welcome
- Sponsor
- Rafiq OKINE
Plasmodium Falciparum Malaria
AMA1-C1/Alhydrogel + CpG 7909 for Malaria
The purpose of this study is to test an experimental malaria vaccine in about 75 healthy adults, 18-45 years of age. The study will also test an experimental adjuvant which is a material added to a vaccine to help the body make…
- Trial name
- NCT00344539
- Testing
- AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®)
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum Infection
Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites
This Phase 1 trial will include 16 subjects who will receive the Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum Parasites (GAP3KO) vaccine administered by the bite of approximately 200 infected Anopheles stephensi…
- Trial name
- NCT03168854
- Testing
- Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain, Malaria challenge
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria,Falciparum
Safety and Efficacy of R0.6C Vaccine
This is a first-in-human phase I, open-label, single-site, dose escalation study to determine the safety, tolerability and Plasmodium falciparum transmission reducing activity of the R0.6C vaccine in two different adjuvant…
- Trial name
- STOP-TRANS (NCT04862416)
- Testing
- R0.6C transmission blocking vaccine
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria
MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B
Pharmacodynamic profiling will also be studied to characterize the effects of MMV390048 on P. falciparum clearance kinetics in healthy subjects using the Induced Blood Stage Malaria (IBSM) challenge model to determine the minimum…
- Trial name
- NCT02783833
- Testing
- MMV390048 40mg, MMV390048 dose to be determined mg
- Where
- Australia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
VAC063C: A Study to Assess Repeat Blood-stage P. Falciparum Infection
This is a clinical study to assess the safety of primary, secondary and tertiary blood-stage controlled human Plasmodium falciparum malaria infection of healthy malaria-naïve UK adults, as well as to evaluate any effect of prior…
- Trial name
- NCT03906474
- Testing
- Blood-stage controlled human P. falciparum malaria infection
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Prophylaxis Against Plasmodium Falciparum Malaria
A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate
Shanghai Wanxing Bio-Pharmaceuticals is currently evaluating one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720.
- Trial name
- NCT00284973
- Testing
- Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.
Healthy
First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants
The primary purpose of this study was to investigate the safety and tolerability of M5717 and to characterize the Pharmacokinetics (PK) /Pharmacodynamic relationship between M5717 PK and parasite clearance in healthy participants…
- Trial name
- NCT03261401
- Testing
- M5717
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Plasmodium Falciparum
Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.
The candidate malaria vaccine RTS,S/AS02A developed by GSK Biologicals demonstrated 30% efficacy against clinical episodes of malaria and approximately 58% efficacy against severe malaria disease.
- Trial name
- NCT00197054
- Testing
- RTS, S/AS01B, RTS, S/AS02A, Rabipur (Rabies) Vaccine
- Where
- Kenya
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria, Falciparum
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.
- Trial name
- NCT07646353
- Testing
- GSK4425689A SC, GSK4425689A IV
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent
This is a single-centre, controlled, open label study using P. falciparum-induced blood stage malaria (IBSM) infection to assess the effectiveness of OZ439 as a gametocytocidal agent, as well as its treatment effects on…
- Trial name
- OZGAM (NCT02431650)
- Testing
- OZ439, Primaquine
- Where
- Australia
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria, Falciparum
A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants
The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the study intervention.
- Trial name
- NCT06171113
- Testing
- GSK4024484C
- Where
- United Kingdom
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration
The purpose of this study is to assess the safety and immunogenicity of novel routes of administration of the candidate malaria vaccines ChAd63 encoding ME-TRAP and MVA encoding ME-TRAP.
- Trial name
- NCT03084289
- Testing
- ChAd63-METRAP, MVA ME-TRAP
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Safety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545])
This study will be the first time that the candidate malaria vaccine Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]) will be tested in malaria endemic populations.
- Trial name
- NCT00431808
- Testing
- Malaria vaccine AMA1 (PfAMA-1-FVO[25-545], AMA1
- Where
- Mali
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- African Malaria Network Trust
Malaria (Plasmodium Falciparum), Malaria Incidence
Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee Settings
The objective is to test the protective effect of permethrin-treated lesus against malaria in young children in refugee settings
- Trial name
- NCT07903324
- Testing
- Factory-treated lesu, Soaked lesu, Untreated lesu
- Where
- Uganda
- Volunteers
- 1,350 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Plasmodium Falciparum Malaria
CS DNA MVA Trial in Mampong, Ghana
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of 2 doses of a malaria vaccine (DNA) followed by a dose of another type of malaria vaccine (MVA) given as a "booster." Forty-eight adults in…
- Trial name
- NCT00377494
- Testing
- MVA-CSO Vaccine, PfCSP DNA (VCL-2510) Vaccine
- Where
- 2 sites in United States, Ghana
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum
Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge)
This study will assess the durability of protection of a single immunisation with the Genetically Attenuated Parasite 2 (GA2) against controlled human malaria infection by rechallenging previously immunised and protected…
- Trial name
- NCT06293339
- Testing
- CHMI with 3D7 malaria
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Malaria
Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults
This is a study designed to assess the safety, tolerability, immunogenicity, and protective efficacy of 2 heterologous prime-boost vaccine regimens in healthy, malaria naïve adults.
- Trial name
- NCT03341754
- Testing
- D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command